Published in Cancer Res on March 22, 2017
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov (2012) 26.98
Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol (2014) 10.04
PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies. Genes Dev (2001) 5.79
Specific inhibition of Stat3 signal transduction by PIAS3. Science (1997) 4.74
Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol (2008) 4.68
Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks. Nature (2009) 4.30
Inhibition of Stat1-mediated gene activation by PIAS1. Proc Natl Acad Sci U S A (1998) 4.12
The SUMO pathway is essential for nuclear integrity and chromosome segregation in mice. Dev Cell (2005) 3.96
The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress. Nature (2009) 3.62
A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science (2011) 3.49
Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst (2004) 3.17
A CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell (2006) 2.95
Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity. Proc Natl Acad Sci U S A (2002) 2.85
Sumoylation: a regulatory protein modification in health and disease. Annu Rev Biochem (2013) 2.66
FAK in cancer: mechanistic findings and clinical applications. Nat Rev Cancer (2014) 2.46
PI3K-PKB/Akt pathway. Cold Spring Harb Perspect Biol (2012) 2.39
Covalent modification of PML by the sentrin family of ubiquitin-like proteins. J Biol Chem (1998) 2.15
PIAS proteins: pleiotropic interactors associated with SUMO. Cell Mol Life Sci (2009) 1.94
Proinflammatory stimuli induce IKKalpha-mediated phosphorylation of PIAS1 to restrict inflammation and immunity. Cell (2007) 1.89
Phospho-regulated SUMO interaction modules connect the SUMO system to CK2 signaling. Mol Cell (2009) 1.66
SUMO1 modification of PTEN regulates tumorigenesis by controlling its association with the plasma membrane. Nat Commun (2012) 1.58
Structure of the Siz/PIAS SUMO E3 ligase Siz1 and determinants required for SUMO modification of PCNA. Mol Cell (2009) 1.46
Myc degradation: dancing with ubiquitin ligases. Proc Natl Acad Sci U S A (2004) 1.31
The ligase PIAS1 restricts natural regulatory T cell differentiation by epigenetic repression. Science (2010) 1.27
PIAS3 suppresses NF-kappaB-mediated transcription by interacting with the p65/RelA subunit. J Biol Chem (2004) 1.25
The RanBP2/RanGAP1*SUMO1/Ubc9 complex is a multisubunit SUMO E3 ligase. Mol Cell (2012) 1.24
Regulation of p53 family members by the ubiquitin-like SUMO system. DNA Repair (Amst) (2009) 1.22
Sumoylation of Mdm2 by protein inhibitor of activated STAT (PIAS) and RanBP2 enzymes. J Biol Chem (2002) 1.21
The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome. Blood (2009) 1.18
The cell biology of disease: Acute promyelocytic leukemia, arsenic, and PML bodies. J Cell Biol (2012) 1.17
The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA. Cancer Res (2012) 1.11
Androgen receptor-interacting protein 3 and other PIAS proteins cooperate with glucocorticoid receptor-interacting protein 1 in steroid receptor-dependent signaling. J Biol Chem (2002) 1.04
PIAS1 is increased in human prostate cancer and enhances proliferation through inhibition of p21. Am J Pathol (2012) 1.02
Akt SUMOylation regulates cell proliferation and tumorigenesis. Cancer Res (2013) 0.99
SUMOylation-regulated protein phosphorylation, evidence from quantitative phosphoproteomics analyses. J Biol Chem (2011) 0.97
c-Myc is targeted to the proteasome for degradation in a SUMOylation-dependent manner, regulated by PIAS1, SENP7 and RNF4. Cell Cycle (2015) 0.92
PIAS1 SUMO ligase regulates the self-renewal and differentiation of hematopoietic stem cells. EMBO J (2013) 0.89
Novel role and mechanism of protein inhibitor of activated STAT1 in spatial learning. EMBO J (2010) 0.88
SUMOylation regulates AKT1 activity. Oncogene (2014) 0.85
A comprehensive compilation of SUMO proteomics. Nat Rev Mol Cell Biol (2016) 0.84
SUMOylation of Myc-family proteins. PLoS One (2014) 0.82
Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma. Blood (2014) 0.82
SUMO5, a Novel Poly-SUMO Isoform, Regulates PML Nuclear Bodies. Sci Rep (2016) 0.82
PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer. Oncogene (2015) 0.79
PIAS1 Promotes Lymphomagenesis through MYC Upregulation. Cell Rep (2016) 0.77
PIAS1-FAK Interaction Promotes the Survival and Progression of Non-Small Cell Lung Cancer. Neoplasia (2016) 0.77
Pharmacological treats for SUMO addicts. Pharmacol Res (2016) 0.77
A Dialog on the First 20 Years of PML Research and the Next 20 Ahead. Front Oncol (2014) 0.77
Pias1 is essential for erythroid and vascular development in the mouse embryo. Dev Biol (2016) 0.76